Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...

Elafibranor for Primary biliary cholangitis (PBC) in 7MM: Market Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Elafibranor Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...

Non-alcoholic Steatohepatitis Therapeutics Market to Grow at a CAGR of 13.6% during the 2022 to 2031 Forecast Period: TMR Study Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis therapeutics market stood at US$ 10.1 billion in 2021 and the global non-alcoholic...

Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...

NASH (Non-Alcoholic Steatohepatitis) Market to Reach USD 21,879 Million by 2028 - Powered by Increasing Pharmaceutical R&D Expenditure and Escalating Obese Population- Vantage Market Research WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH...